Navigation Links
Tris Pharma Announces Availability of the MyKidz® Iron Product Line - the Best Tasting Iron Supplements

MONMOUTH JUNCTION, N.J., March 29, 2011 /PRNewswire/ -- Tris Pharma, Inc., a specialty pharmaceutical company, announced today the highly anticipated re-launch of the MyKidz® Iron product line.  Since the 2007 launch of MyKidz Iron, it has attracted a loyal following of pediatricians, pediatric nurses and mothers.  When the previous marketer decided to focus its product pipeline in a different direction, availability of MyKidz Iron™ became limited, but the need for a great tasting iron supplement remained.  Tris Pharma is stepping-in to provide continuity of care, broader distribution, and ensure that the nutritional needs of infants and toddlers do not go unanswered.

MyKidz Iron products are a line of iron supplements without the strong metallic taste common to other marketed iron supplements.  MyKidz Iron products are based on a patent-pending, taste-neutral formula where the bad-tasting iron is complexed in a polymeric matrix. The formula further contains a berry/banana fruit flavor that makes it a pleasant tasting supplement which helps to increase compliance.  Dr. Louis Reed, a Texas based Pediatrician who has always recommended these supplements, said, "I like MyKidz Iron products because they are the only iron supplements that don't taste like rusty nails, so kids will actually take them."  Additionally, these supplements contain no artificial dyes, alcohol or sugars and the special formula helps to reduce the staining of teeth associated with iron.  

Iron deficiency is a common problem among children, but it is frequently not detected, and it has long-term health implications for children.  It can lead to anemia and/or irreversible effects on children's cognitive and behavioral development.  Studies have shown that 4 percent of 6 month olds and 12 percent of 12 month olds tend to be iron deficient.  Children between the ages of 1-3 years of age have rates of iron deficiency between 6-15 percent.  Pre-term infants, infants who are exclusively breastfed and infants who are at risk for developmental disabilities seem to be at higher risk to develop iron deficiency (1).

"When we received overwhelming feedback," said Ketan Mehta, President and CEO of Tris Pharma, "we realized that there was still a need for a children's iron supplement that was not met by other alternatives.  By making these products available again we, at Tris Pharma, expect the MyKidz Iron product line will positively impact the above statistics."

Three formulations are currently available:

  • MyKidz Iron is an iron supplement with vitamins A, C & D, a 2ml dose delivers 10mg of elemental iron plus 1500 IU of Vitamin A, 35mg of Vitamin C and 400 IU of Vitamin D.
  • MyKidz Iron 10 is a high dose iron only, a 1.5 ml dose delivers 15mg of elemental iron.
  • MyKidz Iron FL is a prescription iron supplement with vitamins A, C & D, plus fluoride.  In addition to the 10mg of elemental iron and above stated vitamin concentrations, it contains .25mg of fluoride per dose for toddlers requiring fluoride supplementation.

Tris Pharma has launched a new website with detailed information about these iron supplements. For more information including full prescribing information, please visit or call toll free (866)697-9283.

About Tris Pharma

Tris Pharma is a specialty pharmaceutical company focused on the research and development of drug delivery technology based products.  Through its OralXR+ platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill.  Tris' research, development, and manufacturing facilities are located in Monmouth Junction, New Jersey, USA. For more information, visit

MyKidz is a trademark of Tris Pharma, Inc.


1.  AAP News Release "AAP OFFERS GUIDANCE TO BOOST IRON LEVELS IN CHILDREN." Website.  October 5, 2010.

© 2011 Tris Pharma, Inc.  Monmouth Junction, NJ.

SOURCE Tris Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
Breaking Medicine News(10 mins):